NCT07186842: A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
- State
- Under way
- Phase
- Phase 1 and Phase 2
- People
- 245 planned
- Started
- 18 Nov 2025
- Primary completion
- May 2030
- Arms
- Dose Escalation: Part C
- Results
- None posted
- 22 Sep 2025: Trial registered
- 18 Nov 2025: Trial started